CHMP recommends Tresiba (Novo Nordisk) for treatment of Diabetes

The CHMP has made recommendation for Tresiba (insulin degludec), a new basal analogue insulin from Novo Nordisk, for the treatment of Diabetes mellitus in adults. It is introduced in a pre-filled pen in two formulations � 100 units/ml and 200 units/ml.

This is the first insulin approved in Europe at a higher strength than the EU-wide standard of 100 units/ml, for many years the only strength of insulin available across the EU. The approval of a 200 units/ml insulin, allowing doses up to 160 units in a single injection, is expected to respond to the growing need for higher-dose insulin. Weight gain, less healthy diets and less physical activity often mean that patients may experience higher levels of insulin resistance and require insulin injections in higher doses to achieve glycaemic control.